Claims for Patent: 10,233,242

✉ Email this page to a colleague

Summary for Patent: 10,233,242

Title:	CTLA4 fusion proteins for the treatment of diabetes
Abstract:	A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
Inventor(s):	Orban; Tihamer (Brookline, MA)
Assignee:	DMNOMORE (London, GB)
Application Number:	14/576,990
Patent Claims:	1. A method of treating type 1 diabetes mellitus in a subject comprising administering an effective amount of a fusion protein composition which comprises a fusion protein and an oil-based carrier, wherein the fusion protein comprises the extracellular domain of CTLA4 and a portion of an immunoglobulin molecule, and wherein the oil-based carrier is a water-in-oil emulsion. 2. The method of claim 1 wherein the composition comprises Abatacept. 3. The method of claim 1 wherein the composition is administered as a pharmaceutically acceptable salt. 4. The method of claim 1, wherein the composition is administered by intravenous infusion. 5. The method of claim 4, wherein the composition is administered by intravenous infusion in about 50 to 200 ml of physiological saline. 6. The method of claim 4, wherein the composition is administered at a dose ranging from about 5 mg/kg to about 50 mg/kg. 7. The method of claim 4, wherein the intravenous infusion of the composition is repeated over time. 8. The method of claim 4, wherein the intravenous infusion of the composition is repeated at least once following a time interval ranging from about one week to about two months. 9. The method of claim 4, wherein the composition is administered at a dose ranging from about 250 to 2000 mg. 10. The method of claim 9, wherein the composition is administered at a dose of 500 mg. 11. The method of claim 9, wherein the composition is administered at a dose of 750 mg. 12. The method of claim 9, wherein the composition is administered at a dose of 1000 mg. 13. The method of claim 1, wherein the subject is white.

Details for Patent 10,233,242

Glossary

Show entries

Subscribe to access the full database, or Try for Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate

Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	December 23, 2005	⤷ Try for Free	2039-04-18
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	July 29, 2011	⤷ Try for Free	2039-04-18
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	June 07, 2016	⤷ Try for Free	2039-04-18
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	March 30, 2017	⤷ Try for Free	2039-04-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.